A stem cell–based therapy initially developed at Memorial Sloan Kettering Cancer Center (MSK) may lead to a new treatment for advanced Parkinson’s disease, according to results from a phase 1 clinical trial reported in Nature.
A stem cell–based therapy initially developed at Memorial Sloan Kettering Cancer Center (MSK) may lead to a new treatment for advanced Parkinson’s disease, according to results from a phase 1 clinical trial reported in Nature.